Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID‐19 vaccine.

Autor: Sechi, A., Pierobon, E., Pezzolo, E., Germi, L., Trevisan, G., Zardo, D., Riva, G., Mondino, S., Naldi, L.
Předmět:
Zdroj: Clinical & Experimental Dermatology; Feb2022, Vol. 47 Issue 2, p437-440, 4p, 2 Color Photographs, 2 Charts
Abstrakt: Besides the more common reactions reflecting aspecific activation of the immune system such as urticaria and cutaneous rash, we observed four rare acute conditions in five recently vaccinated patients [pityriasis rubra pilaris (PRP) in two patients, and Sweet syndrome (SS), pityriasis lichenoides et varioliformis acuta (PLEVA) and erythema multiforme (EM) in one patient each] (Fig. The development and manufacturing of effective vaccines against COVID-19 has been an epic achievement in record time, and we believe that the vaccine will help stop the pandemic. We report five cases of different rare and severe cutaneous conditions arising in close connection with COVID-19 vaccination (Table 1). 1 TableBrief summary of the demographic and clinical features of the patients. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje